Latest News for: ocular

Edit

Ophthalmology and Therapy Publishes Findings Showing Lifestyle-Driven Rise in Ocular Redness and Differentiated Role of LUMIFY®

The Galveston Daily News 24 Feb 2026
VAUGHAN, Ontario--(BUSINESS WIRE)--Feb 24, 2026-- ....
Edit

Ocular Therapeutix™ to Participate in March Investor Conferences

Nasdaq Globe Newswire 24 Feb 2026
24, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc.
Edit

Ophthalmology and Therapy Publishes Findings Showing Lifestyle-Driven Rise in Ocular Redness and Differentiated Role of LUMIFY�

Business Wire 24 Feb 2026
... the causes, burden and management of noninfectious conjunctival hyperemia (ocular redness).
Edit

Ocular Therapeutix™ to Present Detailed SOL-1 Data at the 49th Macula Society Annual Meeting and ...

Nasdaq Globe Newswire 23 Feb 2026
Ocular to present detailed SOL-1 data at the 49th Macula Society Annual Meeting on Friday, February 27, 2026, starting at 1.00 PM PT (4.00 PM ET) ... .
Edit

Notice of Proposed Sale of Securities (Form 144) (Ocular Therapeutix Inc)

Public Technologies 23 Feb 2026
). The text version of this document is not available ... Ocular Therapeutix Inc.
Edit

Formosa Pharmaceuticals Announces Licensing Agreement with Arrotex, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery

PR Newswire 23 Feb 2026
Arrotex's unrivaled sales distribution force and pharmacy access will ensure APP13007's availability to patients recovering from ocular surgery," said Erick Co, President and CEO of Formosa Pharmaceuticals.
Edit

Ocular melanoma Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Delcath System, ...

GetNews 19 Feb 2026
The Key Ocular melanoma Companies in the market include - Immunocore, Delcath Systems, IDEAYA Biosciences, Aura Biosciences, Linnaeus Therapeutics, Turnstone Biologics, Seagen, IDEAYA, Ascentage Pharma, and others ... Key Ocular melanoma Companies.
Edit

Ocular Therapeutix Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About ...

Nasdaq Globe Newswire 18 Feb 2026
... claims on behalf of investors of Ocular Therapeutix, Inc.
Edit

Statement of Changes in Beneficial Ownership (Form 4) (Ocular Therapeutix Inc)

Public Technologies 18 Feb 2026
) FORM 4 ... Form 4 or Form 5 obligations may continue ... 2 ... OCULAR THERAPEUTIX, INC [OCUL] 5 ... C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE 3 ... C/O OCULAR THERAPEUTIX, INC ... (1) Represents shares of common stock of Ocular Therapeutix, Inc ... Ocular Therapeutix Inc.
Edit

Ocular Therapeutix™ Reports Positive Results from Landmark SOL-1 Phase 3 Superiority Trial in Wet AMD

Nasdaq Globe Newswire 17 Feb 2026
First ever successful demonstration of superiority in an FDA-aligned wet AMD trial comparing a novel investigative agent to an approved anti-VEGF treatment ... .
Edit

Uveitis Clinical Trial Pipeline Expands as 15+ Companies Advance 15+ Targeted Ocular Inflammation Therapies Toward ...

GetNews 17 Feb 2026
... Brepocitinib, OCS‑01, Sirolimus (DE‑109), CER‑001, OK‑101, and others that target ocular inflammation via corticosteroid, JAK, cytokine, and TNF‑α pathways or novel delivery technologies.
Edit

Retina’s ‘Sustained’ Moment: Ocular Therapeutix Braces for Game-Changing Phase 3 AXPAXLI Data

The Call 16 Feb 2026
Today, February 16, 2026, Ocular Therapeutix (NASDAQ ... Ocular Therapeutix announced it had completed enrollment ahead of schedule in late 2024, driven by high physician interest in long-acting alternatives.
Edit

Sanofi Tightens Grip on Ocular Therapeutix with Revised Bid as Pivotal SOL-1 Trial Results Loom

The Call 16 Feb 2026
SNY) has reportedly returned to the negotiating table with a significantly "sweetened" revised bid for Ocular Therapeutix (NASDAQ ... The relationship between Sanofi and Ocular Therapeutix has intensified rapidly over the last six months.
Edit

Ocular Therapeutix™ to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026 (Ocular Therapeutix Inc)

Public Technologies 13 Feb 2026
Ocular to host webcast scheduled for Tuesday, February 17, 2026, at 8.00 AM ET ... 13, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc ... About Ocular Therapeutix, Inc. Ocular Therapeutix, Inc ... DEXTENZA® is a registered trademark of Ocular Therapeutix, Inc.
Edit

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Ocular Therapeutix Inc)

Public Technologies 06 Feb 2026
The awards were made as an inducement material to each recipient's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4) ... About Ocular Therapeutix, Inc.

Article Search

tools
×
×
×
×